Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Tamas Shisha"'
Autor:
Giulio Cavalli, Julia Weinmann-Menke, Clive Drakeford, Mi Kwon, Peter Gergely, Tamas Shisha, Pere Barba, Eva Wagner-Drouet, Josefina Cortés Hernández, José María Álvaro-Gracia Álvaro, Ozana Fischer, Beata Kovacs, Frédérique Chaperon, David Pearson, Tiina Kirsilä, Chih-Yung Sean Lee
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/969ef97739404cc7a904da14c37c2bcd
Autor:
Stuart Hawtin, Cédric André, Géraldine Collignon-Zipfel, Simone Appenzeller, Bettina Bannert, Lea Baumgartner, Damian Beck, Claudia Betschart, Thomas Boulay, Hermine I. Brunner, Melanie Ceci, Jonathan Deane, Roland Feifel, Enrico Ferrero, Diego Kyburz, Frederique Lafossas, Pius Loetscher, Christina Merz-Stoeckle, Pierre Michellys, Barbara Nuesslein-Hildesheim, Friedrich Raulf, James S. Rush, Giulia Ruzzante, Thomas Stein, Samantha Zaharevitz, Grazyna Wieczorek, Richard Siegel, Peter Gergely, Tamas Shisha, Tobias Junt
Publikováno v:
Cell Reports Medicine. 4:101036
Autor:
Dmitrij Kollins, Liyi Cen, Josef S Smolen, Tamas Shisha, Juan J. Gomez-Reino, Hans-Peter Tony, Andra Balanescu, Alan Kivitz, Stanley Cohen, Johann Poetzl, Morton Scheinberg
Publikováno v:
Rheumatology. 60:256-262
Objectives This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with reference rituximab (Ref-RTX) up to week 52 of the ASSIST-RA stu
Autor:
Tamas Shisha, Peter Gergely
Publikováno v:
Acta Pharmaceutica Hungarica. 91:93-94
Autor:
Morton Scheinberg, Stanley Cohen, Tamas Shisha, Liyi Cen, Andra Balanescu, Josef S Smolen, Peijuan Zhu, Juan J. Gomez-Reino, Hans-Peter Tony, Alan Kivitz
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesThe aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar efficacy, safety and immunogenicity between GP2013, a biosimilar rituximab, and innovator rituximab (RTX) in patients with
Publikováno v:
Archives of Orthopaedic and Trauma Surgery. 133:589-593
The use of patient-reported outcome questionnaires is recommended in studies of the orthopaedic field. Reliable, validated tools are necessary to ensure the comparability of results across different studies, centers, and countries. The patient-rated
Publikováno v:
European Spine Journal. 15:377-383
In 1925, Calvé described vertebra plana as an aseptic necrosis of bone involving a single vertebral body of the spinal column. This theory was set aside in 1954 by Compere, who concluded that vertebra plana is caused by eosinophilic granuloma and no
Publikováno v:
Annals of the Rheumatic Diseases. 75:512.3-513
Background GP2013 has been developed as a proposed biosimilar to originator rituximab (RTX), by Sandoz, a Novartis Company. The stepwise development program is comprised of structural and functional characterization with highly sensitive analytical m
Autor:
Tamas, Shisha
Publikováno v:
Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases. 7(1)
Complications of the bone-healing process, especially in elderly, osteoporotic patients, are cause of important medical and economical burden. At the same time, there is no clinical study today to have shown the efficacy of a pharmacological treatmen
Publikováno v:
International orthopaedics. 33(2)
This study evaluated the histological changes in muscle tissue after limb lengthening in skeletally mature and immature rabbits and assessed the most vulnerable level of striated muscle. Twenty-three male domestic white rabbits, divided into six grou